MiR-328 May be Considered as an Oncogene in Human Invasive Breast Carcinoma

Abstract

BackgroundThe recent investigations have rendered microRNAs (miRs) as a novel biomarker in cancer research. In fact, alteration in miR expression may be associated with tumor suppression, tumorigenesis, metastasis, and poor prognosis in human breast cancer (BC).ObjectivesThe aim of this clinical experimental study was to measure the miR-328 expression level in breast cancer tissues, at first. Then, we tried to find out any possible correlation between miR-328 and prognostic and predictive biomarkers in BC. Both of these two objectives were investigated for the first time; and we did not find any similar survey measuring the expression level of miR-328 in both tumor and non-tumor breast tissues. This research was conducted in Iran (Ahvaz, Khuzestan), between December 2013 and April 2014. Furthermore, we did not find any previous document investigating the correlation between miR-328 expression level and prognostic factors in BC. Due to the lack of similar studies intending to measure the expression level of miR-328 in tumor and adjacent non-tumor tissues, we decided to carry out a pilot study.MethodsWe measured the expression level of miR-328 by Poly (A) real-time PCR based on SYBR Green-I in 28 fresh samples of BC tissues and 28 samples of normal adjacent tissues, including invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and ductal carcinoma in situ (DCIS). We tried to attribute the results to clinicopathologic features such as status of estrogen and progesterone receptors (ER/PR), HER2/neu (HER2), P53 and also Ki67 labeling (Ki67-LI).ResultsThe results showed that the miR-328 median level of expression was 0.88 (2-ΔΔCt) (25th-75th percentile, 0.07 - 2.34). It means that the expression level increased in tumor tissues compared to normal adjacent tissues (NATs). However, a statistically significant correlation between the miR-328 median expression level and prognostic factors, including pathologic diagnosis, age, and also the status of ER, PR, HER2, and Ki67-LI was not observed (P > 0.05).ConclusionsTherefore, it might be possible to consider miR-328 as an oncogene; but not necessarily an oncomiR, in human BC.

<p>Long Noncoding RNA DIO3OS Hinders Cell Malignant Behaviors of Hepatocellular Carcinoma Cells Through the microRNA-328/Hhip Axis</p>

“…By contrast, DIO3OS promoted cell proliferation and invasion through competing for miR-122 to upregulate ALDOA expression in pancreatic cancer. 24 A plethora of researches on miR-328 have paid much attention to its functions on cell growth, invasion and migration in cancers, including gastric cancer, 25 invasive breast cancer, 26 non-small cell lung cancer, 27 and most importantly, HCC. 28 Additionally, overexpression of metastasis associated in lung adenocarcinoma transcript-1 sequestered cytoplasmic miR-328-3p, culminating in insulin-like growth factor 1 receptor induction to mediate hypoxia-stimulated proliferation of pulmonary artery smooth muscle cells.…”

The microRNA expression signature of CD4+ T cells in the transition of brucellosis into chronicity

“…One of the 28 miRNAs, miR-328, is involved in cancer [ 70 , 71 ], autoimmune [ 72 ], and neuronal diseases [ 73 ]. Tay et al demonstrated another role of miR-328 in the regulation of innate immune cell function by showing that suppression of miR-328 improved bacterial clearance in the lungs.…”

miRNA‑328 overexpression confers cisplatin resistance in non‑small cell lung cancer via targeting of PTEN

“…In-depth studies on the regulatory networks of miRNAs in cancer may provide novel prognostic predictors and therapeutic approaches, beneficial for patients with cancer (10). miR-328 has been reported to promote the progression of various cancer types, including breast and hepatocellular cancers (11,12). In NSCLC, elevations in miR-328 expression levels were associated with brain metastasis (13); however, the role of miR-328 in the development of cisplatin resistance in NSCLC remains unclear.…”